Mainly involved in cancer progression, the expression of all of these aforementioned proteins was decreased after p70S6K1 downregulation/blockade even in the presence of GA, suggesting p70S6K1 activation as a potential therapeutic target for the fight against BC progression in T2DM patients. Here, RPS6KB1 is linked to cancer.